CEB 1050 IN TREATMENT OF AUTISM

该D类研究评估了CEB-1050（盐酸金刚烷胺）在39名自闭症受试者中的有效性。 已发现盐酸金刚烷胺在用于治疗流感、带状疱疹和帕金森病的处方适应症的剂量下具有非竞争性NMD拮抗活性。 许多抗惊厥药也被证明是NMD拮抗剂，一些研究报告金刚烷胺可能在治疗儿童癫痫中具有效用。 分散的报告也表明，金刚烷胺可能是有效的治疗多动症状态。 这些关于金刚烷胺对行为和神经生理参数影响的初步数据表明，它可能对自闭症儿童有一定的疗效。 这是一项随机化研究，并设盲。 收集的所有数据已提交给申办者，并已提交手稿供发表，表明金刚烷胺治疗自闭症具有中度有益作用。

This category D study evaluated the effectiveness of CEB-1050 (amantadine hydrochloride) in thirty-nine subjects with autism. Amantadine hydrochloride had been found to have non-competitive NMD antagonistic activity at doses used for its prescribed indications for the treatment of influenza, herpes zoster, and Parkinson's disease. A number of anticonvulsants have also been shown to be NMD antagonists, and some studies have reported that amantadine may have utility in the treatment of child epilepsy. Scattered reports have also suggested that amantadine may be effective in the treatment of hyperactivity states. These preliminary data about the effects of amantadine on behavioral and neurophysiologic parameters suggested that it might have some effectiveness in children with autism. This was a randomized study, and was blinded. All data collected have been submitted to the sponsor, and a manuscript has been submitted for publication, suggesting a moderate beneficial effect for amantadine in the treatment of autism.